Embodiments of the invention include substituted indole compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition.

Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: ##STR00001##
wherein R, X and R.sup.1 through R.sup.3 are as defined in the specification.

Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

A method of fixating carbon dioxide (CO.sub.2) to form a substituted oxazolidinone is described. The method includes mixing a metal-organic framework (MOF), at least one epoxide, and at least one aromatic amine to form a mixture. The method further includes contacting the mixture with a gas stream containing CO.sub.2 to react the CO.sub.2 in the gas stream with the epoxide and the aromatic amine to form a substituted oxazolidinone. The MOF is a MIL-68(In)X MOF. X is of formula (I): ##STR00001##
where at least one of R.sup.1 to R.sup.4 is an amine-containing group, and R.sup.1 to R.sup.4 are independently an amine-containing group or a hydrogen.

A method of fixating carbon dioxide (CO.sub.2) to form a substituted oxazolidinone is described. The method includes mixing a metal-organic framework (MOF), at least one epoxide, and at least one aromatic amine to form a mixture. The method further includes contacting the mixture with a gas stream containing CO.sub.2 to react the CO.sub.2 in the gas stream with the epoxide and the aromatic amine to form a substituted oxazolidinone. The MOF is a MIL-68(In)X MOF. X is of formula (I): ##STR00001##
where at least one of R.sup.1 to R.sup.4 is an amine-containing group, and R.sup.1 to R.sup.4 are independently an amine-containing group or a hydrogen.